How will this impact your development programs from a regulatory perspective. Get updates on the FDA guidance on Demonstrating Substantial Effectiveness and on Adaptive Trial Designs for clinical trials.
Venn Sciences’ Francois Aubin provides insights on the history, purpose/scope and the framework around these changes.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).